These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22750308)

  • 1. Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.
    Genebat M; Pulido I; Romero-Sánchez MC; González-Serna A; Ferrando-Martínez S; Machmach K; Pacheco YM; Muñoz-Fernández MÁ; Ruiz-Mateos E; Leal M
    Antiviral Res; 2012 Sep; 95(3):207-11. PubMed ID: 22750308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
    Genebat M; de Pablo-Bernal RS; Pulido I; Jiménez-Mejías ME; Martínez O; Pacheco YM; Raffi-El-Idrissi Benhia M; Abad MA; Ruiz-Mateos E; Leal M
    Antiviral Res; 2015 Sep; 121():94-6. PubMed ID: 26122170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
    Genebat M; Ruiz-Mateos E; León JA; González-Serna A; Pulido I; Rivas I; Ferrando-Martínez S; Sánchez B; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Oct; 64(4):845-9. PubMed ID: 19671585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
    Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
    J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance rates between Trofile test and short-term virological response to maraviroc.
    Genebat M; Ruiz-Mateos E; González-Serna A; Pulido I; Muñoz-Fernández MÁ; Ferrando-Martínez S; Leal M
    Antiviral Res; 2011 Feb; 89(2):182-5. PubMed ID: 21134404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
    van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
    Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
    Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
    J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
    Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
    AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
    Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
    Infez Med; 2015 Mar; 23(1):36-43. PubMed ID: 25819049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.
    Ruiz-Mateos E; González-Serna A; Genebat M; Machmach K; Vidal F; Muñoz-Fernández A; Ferrando-Martinez S; Leal M
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4664-9. PubMed ID: 21807977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.
    Baroncelli S; Villani P; Weimer LE; Ladisa N; Francisci D; Tommasi C; Vullo V; Preziosi R; Cicalini S; Cusato M; Galluzzo C; Floridia M; Regazzi M;
    Ann Pharmacother; 2010 May; 44(5):838-43. PubMed ID: 20371753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
    Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Thielen A; Jensen MA; Knapp DJ; Chapman D; Portsmouth S; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    Clin Infect Dis; 2011 Oct; 53(7):732-42. PubMed ID: 21890778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.
    Llibre JM; Rivero A; Rojas JF; Garcia Del Toro M; Herrero C; Arroyo D; Pineda JA; Pasquau J; Masiá M; Crespo M; Blanco JR; Moreno S
    Antiviral Res; 2015 Aug; 120():79-84. PubMed ID: 25977241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune recovery and T cell subset analysis during effective treatment with maraviroc.
    Cossarini F; Galli A; Galli L; Bigoloni A; Salpietro S; Vinci C; Della Torre L; Gianotti N; Spagnuolo V; Lazzarin A; Castagna A; Nozza S
    J Antimicrob Chemother; 2012 Oct; 67(10):2474-8. PubMed ID: 22678730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal use of maraviroc in clinical practice.
    Soriano V; Geretti AM; Perno CF; Fätkenheuer G; Pillay D; Reynes J; Tambussi G; Calvez V; Alcamí J; Rockstroh J
    AIDS; 2008 Nov; 22(17):2231-40. PubMed ID: 18981762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.